Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Inhibitors of apoptosis proteins (IAPs) show promise for treating oral squamous cell carcinoma (OSCC). Targeting IAPs, like XIAP, synergistically enhanced cisplatin efficacy in preclinical models, suggesting a new therapeutic strategy for OSCC.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Oral Squamous Cell Carcinoma (OSCC) is an aggressive cancer with poor survival rates, often linked to chemoresistance.
- Inhibitors of Apoptosis Proteins (IAPs), including IAP1 and XIAP, are implicated in mediating chemotherapy resistance in OSCC.
- Targeting IAPs is an emerging strategy, with several small molecule inhibitors in clinical trials for various cancers.
Purpose Of The Study
- To evaluate and compare the efficacy of three IAP inhibitors.
- To assess their activity as stand-alone agents and sensitizers to cisplatin.
- To investigate their biological activity in a preclinical model of OSCC.
Main Methods
- Utilized cisplatin-sensitive (SCC4) and cisplatin-resistant (SCC4cisR) oral squamous cell carcinoma cell lines.
- Assessed apoptosis via flow cytometry (Annexin V/Propidium Iodide staining).
- Determined IAP protein expression by western blotting and performed gene knockdown using siRNA.
Main Results
- Demonstrated the therapeutic efficacy of Smac mimetic BV6 and XIAP inhibitor Embelin in OSCC.
- Showed synergistic enhancement of cisplatin-induced apoptosis in resistant cells by both IAP inhibitors, partly via XIAP depletion.
- Confirmed that XIAP knockdown potentiated cisplatin-mediated cell death, highlighting XIAP's role in sensitization.
Conclusions
- Provided preclinical evidence for the therapeutic potential of IAP inhibition in OSCC.
- Suggests that IAP inhibitors, particularly those targeting XIAP, could be valuable in overcoming cisplatin resistance.
- Supports the development of IAP-targeted therapies as a novel treatment strategy for oral squamous cell carcinoma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...